an Istitution Experience on Parosteal OsTeosarcoma
Parosteal OsTeosarcoma: a Single Istitution Experience
1 other identifier
observational
220
1 country
1
Brief Summary
single institution cases series review of histological and clinical data
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2018
CompletedStudy Start
First participant enrolled
November 30, 2018
CompletedFirst Posted
Study publicly available on registry
December 7, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2019
CompletedAugust 5, 2021
July 1, 2021
3 months
November 22, 2018
July 30, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
retrospective analysis of cases of Parosteal osteosarcoma
Investigators will exam the presence of progression (dedifferentiation) areas and the relationship of these factors to individual outcome.
at baseline (Day0)
Eligibility Criteria
male and female with diagnosis of parosteal osteosarcoma treated at Rizzoli institute from 01 Jan 1900 to 31 Jul 2018
You may qualify if:
- Male and female patients treated at Rizzoli Institute from 01 Jan 1900 to 31 Jul 2018
- Diagnosis of parosteal osteosarcoma
- Written informed consent prior to any study-specific analysis and/or data collection
You may not qualify if:
- Patients with histological diagnosis different from parosteal osteosarcoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istituto ortopedico Rizzoli
Bologna, 40136, Italy
Related Publications (4)
Han I, Oh JH, Na YG, Moon KC, Kim HS. Clinical outcome of parosteal osteosarcoma. J Surg Oncol. 2008 Feb 1;97(2):146-9. doi: 10.1002/jso.20902.
PMID: 18050289RESULTBertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer. 2005 Jun 1;103(11):2373-82. doi: 10.1002/cncr.21039.
PMID: 15852358RESULTOkada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am. 1994 Mar;76(3):366-78. doi: 10.2106/00004623-199403000-00007.
PMID: 8126042RESULTLaitinen M, Parry M, Albergo JI, Jeys L, Abudu A, Carter S, Sumathi V, Grimer R. The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. Bone Joint J. 2015 Dec;97-B(12):1698-703. doi: 10.1302/0301-620X.97B12.35749.
PMID: 26637687RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2018
First Posted
December 7, 2018
Study Start
November 30, 2018
Primary Completion
February 28, 2019
Study Completion
February 28, 2019
Last Updated
August 5, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will not share
No Individual Patient Data sharing plan has been implemented